BRIEF—ASLAN and BioGenetics agree deal for AML candidate

Singapore-based ASLAN Pharmaceuticals and South Korea’s BioGenetics have expanded a strategic collaboration related to ASLAN003, agreeing a new commercialisation deal.

ASLAN is currently conducting a Phase IIa dose optimisation study of ASLAN003 in AML and expects to complete the study in the first half of 2019.

Under the terms of the deal, both parties will commercialise ASLAN003 in all indications in South Korea. ASLAN will receive an upfront payment of $1 million and up to $8 million in sales and development milestones, plus sales royalties.

BioGenetics will contribute to global R&D costs related to the development in this indication, and will be responsible for the securing of regulatory approvals in South Korea.